Nanomedicine in action: An overview of cancer nanomedicine on the market and in clinical trials

Journal of Nanomaterials

Volumn 2013, Issue , 2013, Pages

  Wang, Ruibing ^a   Billone, Paul S ^a   Mullett, Wayne M ^a  

^a MDS Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE EFFECT; ANIMAL MODEL; CANCER DETECTION; CANCER DIAGNOSTICS; CANCER THERAPEUTICS; CLINICAL TRIAL; COMMERCIAL MARKET; DELIVERY SYSTEMS; FUNDAMENTAL RESEARCH; MEDICAL FIELDS; NANOMEDICINES; NANOPHARMACEUTICALS;

COMMERCE; DIAGNOSIS; DISEASES; EXPERIMENTS; ONCOLOGY;

MEDICAL NANOTECHNOLOGY;

EID: 84872760882     PISSN: 16874110     EISSN: 16874129     Source Type: Journal    
DOI: 10.1155/2013/629681     Document Type: Review

References (70)

1. National Science and Technology Council Committee on Technology, The National Nanotechnology Initiative: Research and Development Leading to a Revolution in Technology and Industry 2005 Washington, DC, USA Office of Sciences and Technology Policy
2. Schafer-Korting M., Drug delivery. The Handbook of Experimental Pharmacology 2010 Berlin, Germany Springer 55 86
3. McNeil S. E., Nanoparticle therapeutics: a personal perspective. Wiley Interdisciplinary Reviews 2009 1 3 264 271 2-s2.0-67649535856 10.1002/wnan.6
4. McNeil S., Nanoparticle therapeutics: a personal perspective. Proceedings of the MRS Functionalized Nanobiomaterials for Medical Applications Workshop 2010 Denver, Colo, USA
5. Bawarski W. E., Chidlowsky E., Bharali D. J., Mousa S. A., Emerging nanopharmaceuticals. Nanomedicine 2008 4 4 273 282 2-s2.0-55949104904 10.1016/j.nano.2008.06.002
6. Choi H. S., Frangioni J. V., Nanoparticles for biomedical imaging: fundamentals of clinical translation. Molecular Imaging 2010 9 6 291 310 2-s2.0-78649739683 10.2310/7290.2010.00031
7. Immordino M. L., Dosio F., Cattel L., Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. International Journal of Nanomedicine 2006 1 3 297 315 2-s2.0-34548482374
8. Green M. R., Manikhas G. M., Orlov S., Afanasyev B., Makhson A. M., Bhar P., Hawkins M. J., Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Annals of Oncology 2006 17 8 1263 1268 2-s2.0-33747887418 10.1093/annonc/mdl104 (Pubitemid 44288216)
9. Chang E. H., Nanomedicines: improving current cancer therapies and and diagnosis. Nanomedicine 2007 3 4 339
10. Stern J. M., Stanfield J., Kabbani W., Hsieh J. T., Cadeddu J. A., Selective prostate cancer thermal ablation with laser activated gold nanoshells. Journal of Urology 2008 179 2 748 753 2-s2.0-38849155323 10.1016/j.juro.2007. 09.018
11. Barenholz Y., Doxil-the first fda-approved nano-drug: lessons learned. Journal of Control Release 2012 160 2 117 134
12. Gabizon A. A., Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Investigation 2001 19 4 424 436 2-s2.0-0035005359 10.1081/CNV-100103136 (Pubitemid 32525189)
13. Gabizon A., Shmeeda H., Barenholz Y., Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clinical Pharmacokinetics 2003 42 5 419 436 2-s2.0-0037681850 10.2165/00003088-200342050- 00002 (Pubitemid 36649037)
14. Čeh B., Winterhalter M., Frederik P. M., Vallner J. J., Lasic D. D., Stealth liposomes: from theory to product. Advanced Drug Delivery Reviews 1997 24 2-3 165 177 2-s2.0-0343632345 10.1016/S0169-409X(96)00456-5 (Pubitemid 27112632)
15. Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R., Martin F., Huang A., Barenholz Y., Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Research 1994 54 4 987 992 2-s2.0-0028349925 (Pubitemid 24085451)
16. Malam Y., Loizidou M., Seifalian A. M., Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends in Pharmacological Sciences 2009 30 11 592 599 2-s2.0-70350292588 10.1016/j.tips.2009.08.004
17. Muggia F. M., Hainsworth J. D., Jeffers S., Miller P., Groshen S., Tan M., Roman L., Uziely B., Muderspach L., Garcia A., Burnett A., Greco F. A., Morrow C. P., Paradiso L. J., Liang L. J., Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. Journal of Clinical Oncology 1997 15 3 987 993 2-s2.0-0031055830 (Pubitemid 27106281)
18. Gabizon A., Goren D., Horowitz A. T., Tzemach D., Lossos A., Siegal T., Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Advanced Drug Delivery Reviews 1997 24 2-3 337 344 2-s2.0-0343923453 10.1016/S0169-409X(96)00476-0 (Pubitemid 27112652)
19. Waterhouse D. N., Tardi P. G., Mayer L. D., Bally M. B., A comparison of liposomal formulations of doxorubicin with Drug Administered in free form: changing toxicity profiles. Drug Safety 2001 24 12 903 920 2-s2.0-0035164058 (Pubitemid 33078196)
20. Lammers T., Hennink W. E., Storm G., Tumour-targeted nanomedicines: principles and practice. British Journal of Cancer 2008 99 3 392 397 2-s2.0-48349107149 10.1038/sj.bjc.6604483
21. Harris L., Batist G., Belt R., Rovira D., Navari R., Azarnia N., Welles L., Winer E., Garrett T., Blayney D., Elias L., Mortimer J., Needles B., Webb T., Atiba J., Bickers J., Godfrey T., Love R., Osborn D., Aisner J., Anderson T., Butler D., Calabresi P., Feldman L., Kerr R., Nevinny H., Reynolds C., Schneider A., Tweedy C., Whaley W., Demattia M., Harper G., Moroose R., Staszewski H., Begas A., Dutcher J., Ellis R., Fleming G., Garcia M., Granick J., Kloss J., Roberts M., Sanchez F., Silver R., Taylor H., Liposome- encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002 94 1 25 36 2-s2.0-0036142158 10.1002/cncr.10201 (Pubitemid 34049039)
22. Alberts D. S., Muggia F. M., Carmichael J., Winer E. P., Jahanzeb M., Venook A. P., Skubitz K. M., Rivera E., Sparano J. A., Dibella N. J., Stewart S. J., Kavanagh J. J., Gabizon A. A., Efficacy and safety of liposomal anthracyclines in Phase I/II clinical trials. Seminars in Oncology 2004 31 13 53 90 2-s2.0-19944411434 10.1053/j.seminoncol.2004.08.010 (Pubitemid 40023242)
23. Sopherion Therapeutics, Myocet: doxorubicin hydrochloride (Liposome) for injection. 2001, http://www.sopherion.com/pdf/PIEnglishv0-2.pdf
24. Forssen E. A., The design and development of DaunoXome for solid tumor targeting in vivo. Advanced Drug Delivery Reviews 1997 24 2-3 133 150 2-s2.0-0342617568 10.1016/S0169-409X(96)00453-X (Pubitemid 27112629)
25. Fassas A., Anagnostopoulos A., The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia. Leukemia and Lymphoma 2005 46 6 795 802 2-s2.0-21844468233 10.1080/10428190500052438 (Pubitemid 40959668)
26. Sparano J. A., Winer E. P., Liposomal anthracyclines for breast cancer. Seminars in Oncology 2001 28 4 32 40 2-s2.0-0034835602 (Pubitemid 32879937)
27. Forssen E. A., Ross M. E., DaunoXome treatment of solid tumors preclinical and clinical investigations. Journal of Liposome Research 1994 4 1 481 512 2-s2.0-0028204863 (Pubitemid 24130557)
28. Allen T. M., Martin F. J., Advantages of liposomal delivery systems for anthracyclines. Seminars in Oncology 2004 31 supplement 13 5 15 2-s2.0-11144310022 10.1053/j.seminoncol.2004.08.001 (Pubitemid 40023239)
29. Galen US, DaunoXome: daunorubicin citrate liposome injection. 2011, http://daunoxome.com/downloads/DaunoXome%20PI.pdf
30. Clinicaltrials.gov,. U.S. National Institutes of Health, Search for "DaunoXome" AND "Phase 3" http://clinicaltrials.gov/
31. Chang H. I., Cheng M. Y., Yeh M. K., Clinically-proven liposome-based drug delivery: formulation, characterization and therapeutic efficacy. 2012 1 195 10. 4172/scientificreports. 195
32. Dromi S., Frenkel V., Luk A., Traughber B., Angstadt M., Bur M., Poff J., Xie J., Libutti S. K., Li K. C. P., Wood B. J., Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clinical Cancer Research 2007 13 9 2722 2727 2-s2.0-34249008526 10.1158/1078-0432.CCR-06-2443 (Pubitemid 46788041)
33. Poon R. T. P., Borys N., Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer. Expert Opinion on Pharmacotherapy 2009 10 2 333 343 2-s2.0-65649146495 10.1517/14656560802677874
34. Clinicaltrials.gov,. U.S. National Institutes of Health, Search for "ThermoDo" AND "Phase 3" http://clinicaltrials.gov/
35. Celsion Progresses with ThermoDox. 2012, http://finance.yahoo.com/news/ celsion-progresses-thermodox-211903842.html
36. Clinicaltrials.gov. U.S. National Institutes of Health, Search for "ThermoDox" http://clinicaltrials.gov/
37. Schiff P. B., Horwitz S. B., Taxol stabilizes microtubules in mouse fibroblast cells. Proceedings of the National Academy of Sciences of the United States of America 1980 77 3 1561 1565 2-s2.0-0000297058 (Pubitemid 10073801)
38. Guarneri V., Dieci M. V., Conte P., Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. Expert Opinion in Pharmacotherapy 2012 13 3 395 406
39. Hawkins M. J., Soon-Shiong P., Desai N., Protein nanoparticles as drug carriers in clinical medicine. Advanced Drug Delivery Reviews 2008 60 8 876 885 2-s2.0-42649132499 10.1016/j.addr.2007.08.044
40. Kratz F., Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. Journal of Controlled Release 2008 132 3 171 183 2-s2.0-56949084877 10.1016/j.jconrel.2008.05.010
41. Desai N., Trieu V., Yao Z., Louie L., Ci S., Yang A., Tao C., De T., Beals B., Dykes D., Noker P., Yao R., Labao E., Hawkins M., Soon-Shiong P., Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clinical Cancer Research 2006 12 4 1317 1324 2-s2.0-33644753906 10.1158/1078-0432.CCR-05-1634 (Pubitemid 43342524)
42. Abraxis BioScience LLC, ABRAXANE Healthcare Professional Prescribing Information. http://www.abraxane.com/hcp/download/Abraxane-Prescribing- Information.pdf
43. Epeius Biotech,. http://www.epeiusbiotech.com/oncology-RexinG-factsheet. asp
44. Gordon E. M., Hall F. L., Rexin-G, a targeted genetic medicine for cancer. Expert Opinion on Biological Therapy 2010 10 5 819 832 2-s2.0-77951123789 10.1517/14712598.2010.481666
45. Chawla S. P., Chua V. S., Fernandez L., Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy- resistant sarcoma and osteosarcoma. Molecular Therapy 2009 17 9 1651 1657 10.1038/mt.2009.126
46. Chawla S. P., Chua V. S., Fernandez L., Advanced phase I/II studies of targeted gene delivery in vivo: intravenous rexin-G for gemcitabine-resistant metastatic pancreatic cancer. Molecular Therapy 2010 18 2 435 441 10.1038/mt.2009.228
47. Galanis E., Carlson S. K., Foster N. R., Lowe V., Quevedo F., McWilliams R. R., Grothey A., Jatoi A., Alberts S. R., Rubin J., Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer. Molecular Therapy 2008 16 5 979 984 2-s2.0-42549139673 10.1038/mt.2008.29 (Pubitemid 351587110)
48. Broome J. D., Evidence that the L-asparaginase activity of guinea pig serum is responsible for its antilymphoma effects. Nature 1961 191 4793 1114 1115 2-s2.0-36949081498 10.1038/1911114a0
49. Tallal L., Tan C., Oettgen H., Wollner N., McCarthy M., Helson L., Burchenal J., Karnofsky D., Murphy M. L., E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 childrens. Cancer 1970 25 2 306 320 2-s2.0-0014736757
50. Avramis V. I., Tiwari P. N., Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. International journal of nanomedicine 2006 1 3 241 254 2-s2.0-34548776939
51. Gaynon P. S., Childhood acute lymphoblastic leukaemia and relapse. British Journal of Hematology 2005 131 5 579 587 10.1111/j.1365-2141.2005.05773. x (Pubitemid 43903802)
52. Jarrar M., Gaynon P. S., Periclou A. P., Fu C., Harris R. E., Stram D., Altman A., Bostrom B., Breneman J., Steele D., Trigg M., Zipf T., Avramis V. I., Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group Study (CCG-1941). Pediatric Blood and Cancer 2006 47 2 141 146 2-s2.0-33745765204 10.1002/pbc.20713 (Pubitemid 44025245)
53. Lenz H. J., Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007 12 5 601 609 2-s2.0-35548983383 10.1634/ theoncologist.12-5-601 (Pubitemid 350012124)
54. Reimer P., Tombach B., Hepatic MRI with SPIO: detection and characterization of focal liver lesions. European Radiology 1998 8 7 1198 1204 2-s2.0-0031616365 (Pubitemid 128662777)
55. Wang Y. X. J., Hussain S. M., Krestin G. P., Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. European Radiology 2001 11 11 2319 2331 2-s2.0-0034753215 10.1007/s003300100908 (Pubitemid 33041104)
56. Reimer P., Balzer T., Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. European Radiology 2003 13 6 1266 1276 2-s2.0-0038756705 (Pubitemid 36790627)
57. Hamm B., Staks T., Taupitz M., Maibauer R., Speidel A., Huppertz A., Frenzel T., Lawaczeck R., Wolf K. J., Lange L., Contrast-enhanced MR imaging of liver and spleen: first experience in humans with a new superparamagnetic iron oxide. Journal of Magnetic Resonance Imaging 1994 4 5 659 668 2-s2.0-0028511368
58. Hamm B., Staks T., Taupitz M., A new superparamagnetic iron oxide contrast agent for magnetic resonance imaging. Investigative Radiology 1994 29 2 S87 S89 2-s2.0-0028221216 (Pubitemid 24221070)
59. Weissleder R., Stark D. D., Engelstad B. L., Bacon B. R., Compton C. C., White D. L., Jacobs P., Lewis J., Superparamagnetic iron oxide: pharmacokinetics and toxicity. American Journal of Roentgenology 1989 152 1 167 173 2-s2.0-0024505526 (Pubitemid 19024086)
60. Wang Y. X., Superparamagnetic iron oxide based MRI contrast agents: current status of clinical application. Quantitative Imaging in Medicine and Surgery 2011 1 1 35 40
61. Zhang L., Gu F. X., Chan J. M., Wang A. Z., Langer R. S., Farokhzad O. C., Nanoparticles in medicine: therapeutic applications and developments. Clinical Pharmacology and Therapeutics 2008 83 5 761 769 2-s2.0-42349094203 10.1038/sj.clpt.6100400 (Pubitemid 351556021)
62. Tiwari M., Nano cancer therapy strategies. Journal of Cancer Research and Therapeutics 2012 8 1 19 22 10.4103/0973-1482.95168
63. Karve S., Werner M. E., Sukumar R., Cummings N. D., Copp J. A., Wang E. C., Li C., Sethi M., Chen R. C., Pacold M. E., Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery. Proceedings of the National Academy of Sciences of the United States of America 2012 109 21 8230 8235
64. Shim G., Lee S., Choi H., Lee J., Kim C. W., Byun Y., Oh Y. K., Nanomedicines for receptor-mediated tumor targeting. Recent Patents on Nanomedicine 2012 1 2 138 148
65. Naveed A., Fessi H., Elaissari A., Theranostic applications of nanoparticles in cancer. Drug Discovery Today 2012 17 17-18 928 934 10.1016/j.drudis.2012.03.010
66. Wang A. Z., Langer R., Farokhzad O. C., Nanoparticle delivery of cancer drugs. Annual Review of Medicine 2012 63 185 198
67. Melancn M. P., Stafford R. J., Li C., Challenges to effective cancer nanotheranostics. Journal of Controlled Release 2012 164 177 182
68. Trivedi N., Patel N., Upadhyay U. M., Sha S., Gold nanoparticulate drug delivery system: a review. Pharmacie Globale International Journal of Comphrehesive Pharmacy 2012 3 6 1 5
69. Libutti S. K., Paciotti G. F., Myer L., Haynes R., Gannon W., Walker M., Results of a completed phase I clinical trial of CYT-6091: a peglated colloidal gold-TNF. Nanomedicine 2009 27 15 3586
70. Libutti S. K., Paciotti G. F., Byrnes A. A., Alexander H. R., Gannon W. E., Walker M., Seidel G. D., Yuldasheva N., Tamarkin L., Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clinical Cancer Research 2010 16 24 6139 6149 2-s2.0-78650348824 10.1158/1078-0432.CCR-10-0978